NOVAVAX INC

NVAX - CIK 0001000694

Market cap$1.84 B

Rank#2165

SEC filings1,627

NOVAVAX INC trades as NVAX and has a market capitalization of $1.84 B, making it the #2165 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.12B, up 64.7% from the prior year and net income of $440.30M. This page tracks NOVAVAX INC through 1,627 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.12BFY 2025

Net income (latest FY)$440.30MFY 2025

Operating cash flow (latest FY)-$244.63MFY 2025

Total assets (latest FY)$1.18BFY 2025

Net margin39.2%latest FY

Financial performance

Over the last 9 fiscal years NOVAVAX INC's revenue grew from $15.35M to $1.12B, a compound annual growth rate of 61.1%. Net profit margin expanded from -1823.5% to 39.2% over the same period - every figure below comes from the company's audited annual filings.

NVAX annual revenueView details

Key statistics

Market cap: $1.84 B
Share price (derived)market cap / shares outstanding: $11.19
P/E ratio (trailing FY): 4.2
EPS (diluted)FY 2025: $2.58
Shares outstandingas of 2026-04-30: 0.16B
Total equityas of 2025-06-30: $37.63M
Return on equity: 1170.2%
Long-term debtas of 2026-03-31: $291.04M

Latest filings

Filing	Type	Filed
SCHEDULE 13D/A	-	2026-05-15
Insider sale notice	144	2026-05-07
Major company event	8-K	2026-05-06
Quarterly report	10-Q	2026-05-06
SCHEDULE 13G	-	2026-04-30
Insider trade	4	2026-04-28
Proxy materials	DEFA14A	2026-04-27
Proxy statement	DEF 14A	2026-04-27